Noom ยท Growth & Business Model

Whole Health

A reusable framework that runs the full commerce lifecycle for Noom's Whole Health portfolio, so a new product can launch, convert, and scale on a system that already exists.

Role
Design Lead, Whole Health
Company
Noom
PM
Niki Larsen
Focus
Growth, LTV, product launches
Scope
Framework across the lifecycle
The reusable framework
One system, the full product lifecycle
Product pagesUpsell pitchCheckoutEligibilityCancellationIn-app upsell
powers

A growing portfolio

Biomarkers, Metabolic, Sermorelin, and more products launching every month.

Every user segment

Tailored paths for free, weight, and medication users from one shared system.

The whole journey

Discover, pitch, buy, qualify, and manage, all on the same foundation.

+81%
Biomarkers over its month-one volume target
+2.5×
Sermorelin cross-sell, versus expectations
1 system
behind every back-to-back launch

The opportunity

Noom was expanding beyond weight loss into a family of health products, each needing its own commerce experience to cross-sell customers, reach new segments, and raise lifetime value. Building every funnel one-off, from product page to checkout to cancellation, would never keep pace with back-to-back launches.

My role

I led design for the growth and go-to-market surface. I owned the reusable component system and the product-page and ad-placement architecture, partnered with my PM on the eligibility, purchase, and cancellation logic, and guided product marketing and creative on how the system applied to their copy and assets.

The real design work: what to standardize, and what to let flex

The hard part was not building templates. It was judgment. My PM and I mapped every product's purchase, eligibility, and cancellation flow, found the shared skeleton underneath, then went product by product on where a path genuinely had to diverge. Too much reuse and every launch reads generic; too much nuance and there is no leverage left. Deciding where to reuse and where to diverge was the design.

What I did

  • Mapped every product's purchase, eligibility, and cancellation flow to find the shared skeleton.
  • Built a reusable component system spanning the product page, ad placements, eligibility, checkout, and cancellation.
  • Made deliberate calls, product by product, on where a flow had to diverge to respect real differences.
  • Shipped launches back to back on the system, each faster and cleaner than the last.
Biomarkers product page
BiomarkersOne-time at-home kit
Metabolic product page
MetabolicDaily supplement, subscription
Sermorelin product page
SermorelinClinician-prescribed program
NAD+ product page
NAD+Prescribed program
Oxytocin product page
OxytocinDaily peptide

Swipe to explore the portfolio

Beyond the product page: one funnel, with product-specific variants

The product page is only the front door. The same system runs checkout, eligibility, and cancellation across every product, and the craft is in the variants. A medication product gates on clinical eligibility and asks about side effects when someone cancels; a supplement skips both. Checkout itself adapts to what we already know about the user.

Free userCheckout for a free user, full form
Weight userCheckout for a weight user, partly known
Med userCheckout for a med user, review and submit

One checkout, three states. A free user fills the whole form; a weight user is part-known; a med user just reviews and submits. Same system, less friction the more it already knows.

NAD+ eligibility flow map

The NAD+ eligibility flow at a glance. Every conditional branch and rejection state the logic had to resolve, from location and clinical criteria to the no-active-subscription fallback. Medication products gate here; supplements skip it entirely.

Metabolic cancellation flow map

The Metabolic cancellation flow. Reason capture, product-specific branches like side-effect questions for a medication, counteroffers, and the retention logic underneath, all built as variants on one shared cancellation system.

What the system delivered

Biomarkers exceeded its month-one volume target by about 81%, and roughly 35% in month two. Sermorelin's cross-sell purchase rate is outperforming expectations by about 2.5 times. NAD+ launched most recently, on the same framework. The leverage is the point: the system is now the template for every launch that comes next, and that outlasts any single SKU.

What I would carry forward

The reuse-versus-nuance line was the hardest call, and I drew it on judgment. Next time I would instrument it: define upfront what tells us a divergence is earning its cost, and revisit after the second launch, not the fourth.